Skip Navigation

European Heart Journal 2002 23(1):50-58; doi:10.1053/euhj.2001.2711
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brown, R.E.
Right arrow Articles by Simoons, M.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, R.E.
Right arrow Articles by Simoons, M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Cost effectiveness of eptifibatide in acute coronary syndromes. An economic analysis of Western European patients enrolled in the PURSUIT trial

R.E. Browna,f1, R.A. Hendersonb, D. Kosterc, J. Huttona and M.L. Simoonsd

a MEDTAP International Inc, London, U.K.
b Department of Cardiology, Nottingham City Hospital, Nottingham, U.K.
c Ingenix Pharmaceutical Services, Basking Ridge, NJ, U.S.A.
d Thoraxcenter University Hospital Rotterdam, Rotterdam, The Netherlands

revised March 27, 2001; accepted March 28, 2001

Abstract

Aims To assess the direct medical costs and cost effectiveness of routine eptifibatide use amongst patients with unstable angina and myocardial infarction without persistent ST-segment elevation in the Western European subgroup of the PURSUIT trial.

Methods and Results Health care resources were collected for the Western European PURSUIT trial patients (n=3697). Unit costs for major resources were developed within six countries using a consistent bottom-up methodology. Resource consumption from the Western European population was used to calculate the average direct medical costs per patient in the eptifibatide and placebo arms of the trial. Eptifibatide was estimated to cost 524 Euros per treatment. Long-term survival estimated from the 6-month trial survival data and combined with the cost data was used to calculate cost-effectiveness ratios. Additionally, cost per death and non-fatal myocardial infarction at 30 days was calculated. Sensitivity analyses were conducted on the discount rate and resource consumption. Cost-effectiveness ratios ranged from 9603 Euros to 18115 Euros per year of life saved with 3% discount. Using resource consumption based on countries with low coronary arteriography rates, the cost per year of life saved was between 3329 Euros and 10079 Euros. Using resource consumption based on high coronary arteriography rate countries, the cost per year of life saved was between 17089 Euros and 24099 Euros. Assuming no difference in treatment costs except for the addition of eptifibatide, the incremental cost per year of life saved was 23818 Euros.

Conclusions Routine eptifibatide use was associated with a reduction in the combined end-point of death and myocardial infarction at 30 days, which was sustained at 6 months. Long-term projections indicate a modest increase in survival in eptifibatide patients. These data translate into cost-effectiveness ratios that compare favourably with other new technologies that are currently in use.

Key Words: Resources, costs, eptifibatide, cost effectiveness, unstable angina

f1 Correspondence: Ruth E. Brown, MEDTAP International Inc., 20 Bloomsbury Square, London WC1A 2NS, U.K.

References

  1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of acute artery disease and the acute coronary syndromes (First of two parts). N Engl J Med. 1992;326:242–250[ISI][Medline]
  2. Harker LA. Strategies for inhibiting the effects of thrombin. Blood Coagul Fibrinolysis. 1994;5:S47–S58
  3. N Engl J Med. 1998;339:436–443[Abstract/Free Full Text]
  4. Circulation. 1998;97:2386–2395[Abstract/Free Full Text]
  5. N Engl J Med. 1998;338:1498–1505[Abstract/Free Full Text]
  6. N Engl J Med. 1998;338:1488–1497[Abstract/Free Full Text]
  7. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  8. N Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  9. Lancet. 1997;349:1429–1435[CrossRef][ISI][Medline]
  10. Lancet. 1997;349:1422–1428[CrossRef][ISI][Medline]
  11. Circulation. 1997;96:1445–1453[Abstract/Free Full Text]
  12. Harrington RA, Lincoff M, Berdan LG. Maintenance of clinical benefit at six-months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. Circulation. 1998;:359
  13. Henderson R, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial. Eur Heart J Supplements. 1999;1:N35–N41
  14. Brown, RE, McElwee, N, Hutton, J, Conducting cost analyses for international clinical trials, 1998, 49
  15. Mark DB, Hlatky MA, Califf RM. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424[Abstract/Free Full Text]
  16. Mark DB, Harrington RA, Lincoff AM. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation. 1999;101:366–371
  17. Akkerhuis KM, Deckers JW, Boersma E. Geographic variability in outcomes within an international trial of glycoprotein Iib/IIIa inhibition in patients with acute coronary syndromes. Cur Heart J. 2000;21:371–381
  18. VandenBergh MF, van Hout BA, Maat AP. Cost effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol. 1996;17:789–792
  19. Laupacis A, Teen D, Detsky A. How attractive does a technology have to be to warrant adoption and utilisation? Can Med Assoc J. 1992;146:473–481[Abstract]
  20. Mark DB. Medical economics in cardiovascular medicine. Topol EJ. Textbook of Cardiovascular Medicine. New York: Lippincott-Raven; 1997. p. 1033–1062
  21. Tengs TO, Adams ME, Pliskin JS. Five-hundred life-saving interventions and their cost-effectiveness. Risk analysis. 1995;15:369–390[CrossRef][ISI][Medline]
  22. Johannesson M, Jonsson B, Kjekshus J. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332–336[Abstract/Free Full Text]
  23. Ashraf T, Hay JW, Pitt B. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409–414[CrossRef][ISI][Medline]
  24. Krumholz HM, Pasternak RC, Weinstein MC. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992;327:7–13[Abstract]
  25. Mushlin AI, Hall WJ, Zwanziger J. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97:2129–2135[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Med Decis MakingHome page
A. Manca, P. C. Lambert, M. Sculpher, and N. Rice
Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling
Med Decis Making, August 1, 2007; 27(4): 471 - 490.
[Abstract] [PDF]

Home page
 CirculationHome page
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons, et al.
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial
Circulation, January 28, 2003; 107(3): 437 - 442.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Emergency Med.Home page
Eptifibatide Is Cost-Effective in Non-ST-Segment Elevation ACS
Journal Watch Emergency Medicine, February 27, 2002; 2002(227): 11 - 11.
[Full Text]

Home page
 Eur Heart JHome page
A. Baumbach and K. R. Karsch
Pricing a year of life: a necessary exercise in modern health care
Eur. Heart J., January 1, 2002; 23(1): 5 - 7.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brown, R.E.
Right arrow Articles by Simoons, M.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, R.E.
Right arrow Articles by Simoons, M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?